Myristoylation-Dependent Palmitoylation of the Receptor Tyrosine Kinase Adaptor FRS2α.


Journal

Biochemistry
ISSN: 1520-4995
Titre abrégé: Biochemistry
Pays: United States
ID NLM: 0370623

Informations de publication

Date de publication:
25 06 2019
Historique:
pubmed: 12 6 2019
medline: 3 6 2020
entrez: 12 6 2019
Statut: ppublish

Résumé

An early step in signaling from activated receptor tyrosine kinases (RTKs) is the recruitment of cytosolic adaptor proteins to autophosphorylated tyrosines in the receptor cytoplasmic domains. Fibroblast growth factor receptor substrate 2α (FRS2α) associates via its phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). Upon FGFR activation, FRS2α undergoes phosphorylation on multiple tyrosines, triggering recruitment of the adaptor Grb2 and the tyrosine phosphatase Shp2, resulting in stimulation of PI3K/AKT and MAPK signaling pathways. FRS2α also undergoes N-myristoylation, which was shown to be important for its localization to membranes and its ability to stimulate downstream signaling events (Kouhara et al., 1997). Here we show that FRS2α is also palmitoylated in cells and that cysteines 4 and 5 account for the entire modification. We further show that mutation of those two cysteines interferes with FRS2α localization to the plasma membrane (PM), and we quantify this observation using fluorescence fluctuation spectroscopy approaches. Importantly, prevention of myristoylation by introduction of a G2A mutation also abrogates palmitoylation, raising the possibility that signaling defects previously ascribed to the G2A mutant may actually be due to a failure of that mutant to undergo palmitoylation. Our results demonstrate that FRS2α undergoes coupled myristoylation and palmitoylation. Unlike stable cotranslational modifications, such as myristoylation and prenylation, palmitoylation is reversible due to the relative lability of the thioester linkage. Therefore, palmitoylation may provide a mechanism, in addition to phosphorylation, for dynamic regulation of FRS2 and its downstream signaling pathways.

Identifiants

pubmed: 31184863
doi: 10.1021/acs.biochem.9b00299
pmc: PMC6800032
mid: NIHMS1053900
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
FRS2 protein, human 0
Membrane Proteins 0
enhanced green fluorescent protein 0
Myristic Acid 0I3V7S25AW
Green Fluorescent Proteins 147336-22-9
Palmitic Acid 2V16EO95H1
Cysteine K848JZ4886

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2809-2813

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM064589
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM113079
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121536
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI083196
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Proteomics. 2004 Jun;4(6):1626-32
pubmed: 15174132
J Biol Chem. 2012 Jan 2;287(1):523-30
pubmed: 22081607
Mol Cell Biol. 2000 Feb;20(3):979-89
pubmed: 10629055
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5514-9
pubmed: 24706887
J Biol Chem. 2009 Jun 5;284(23):15980-92
pubmed: 19339244
J Biol Chem. 2003 Apr 18;278(16):13803-9
pubmed: 12571252
J Biol Chem. 2001 Oct 26;276(43):39501-4
pubmed: 11527981
Sci Rep. 2016 Jun 16;6:28249
pubmed: 27306108
Science. 2006 Dec 1;314(5804):1458-61
pubmed: 17095657
J Biol Chem. 2018 Apr 27;293(17):6434-6448
pubmed: 29540482
Biophys J. 2010 Aug 4;99(3):979-88
pubmed: 20682277
J Proteome Res. 2018 May 4;17(5):1907-1922
pubmed: 29575903
Appl Spectrosc. 2004 May;58(5):122A-137A
pubmed: 15165323
Cell. 1997 May 30;89(5):693-702
pubmed: 9182757
Bioinformatics. 2006 Apr 1;22(7):894-6
pubmed: 16434441
Expert Opin Ther Targets. 2009 Jun;13(6):689-700
pubmed: 19456272
Biochemistry. 2010 Aug 3;49(30):6305-16
pubmed: 20583817
J Genet Genomics. 2015 Oct 20;42(10):521-529
pubmed: 26554907
J Cell Biol. 2014 Apr 14;205(1):113-26
pubmed: 24711504
Cancer Sci. 2008 Jul;99(7):1319-25
pubmed: 18452557
Nat Methods. 2011 Nov 06;9(1):84-9
pubmed: 22056678
Science. 2010 Jan 1;327(5961):46-50
pubmed: 20044567
Biophys J. 2017 Jul 11;113(1):138-147
pubmed: 28700912
FEBS J. 2008 May;275(9):2055-66
pubmed: 18355321
Anal Biochem. 2015 Jul 1;480:11-20
pubmed: 25862080

Auteurs

Jared Hennen (J)

School of Physics and Astronomy , University of Minnesota , Minneapolis , Minnesota 55455 , United States.

Isaac Angert (I)

School of Physics and Astronomy , University of Minnesota , Minneapolis , Minnesota 55455 , United States.

Yan Chen (Y)

School of Physics and Astronomy , University of Minnesota , Minneapolis , Minnesota 55455 , United States.

Joachim D Mueller (JD)

School of Physics and Astronomy , University of Minnesota , Minneapolis , Minnesota 55455 , United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH